Announcements
- aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update
- aTyr Pharma to Participate in April Investor Conferences
- aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
- aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results
- aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants
- aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity
- aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor
- aTyr Pharma to Present at November Investor Conferences
- aTyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Patients with SSc-ILD
- aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes
More ▼
Key statistics
On Tuesday, aTyr Pharma Inc (471A:DEU) closed at 1.45, 47.21% above the 52 week low of 0.985 set on Nov 15, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.45 |
---|---|
High | 1.52 |
Low | 1.45 |
Bid | 1.46 |
Offer | 1.51 |
Previous close | 1.46 |
Average volume | 703.11 |
---|---|
Shares outstanding | 67.94m |
Free float | 66.16m |
P/E (TTM) | -- |
Market cap | 108.03m USD |
EPS (TTM) | -0.9537 USD |
Data delayed at least 15 minutes, as of Apr 30 2024.
More ▼